SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Anticipation around SELLASs event-driven Phase 3 REGAL trial dominates discussion, with traders focused on the 80-event threshold needed to trigger final analysis. Bulls interpret the prolonged wait since the last disclosed count as a possible sign of longer survival on GPS, while skeptics stress that the delay does not prove efficacy and the eventual readout remains uncertain; buyout speculation adds to the chatter.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rises amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about oil-supply disruptions. Traders are divided over whether geopolitical risks will keep prices elevated or whether Iran-US deal headlines and Russian supply relief will unwind the risk premium; some also question the reliability of the headlines.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows has focused discussion on waning confidence in Trump ahead of the midterms and concerns about Truth Socials engagement and the companys underlying business. Bearish traders see room for further declines, while some view the selloff as an opportunity for a short-term bounce.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price weakness and underperformance versus the biotech sector despite revenue growth from ORLADEYO. Traders are split between viewing the valuation as overly discounted and worrying that managements acquisition-focused strategy, dilution and HAE competition leave the stock dependent on future navenibart and pipeline results.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff and weak performance versus peers as traders debate neocloud financing risks and broader concerns about AI infrastructure spending. The co-CEOs statement that data centers carry no debt and customer prepayments help fund GPU costs has reassured some investors, while others remain concerned about execution and the stocks continued weakness.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its Prenatal Health testing business to Labcorp for cash is driving the sharp rally, with traders viewing the proceeds as a boost to liquidity and a chance to refocus on cancer diagnostics. Others question the sale of a major business, while much of the discussion centers on the surge, breakout levels and short-covering speculation; the transaction remains subject to closing conditions.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is drawing attention amid HSBCs bearish assessment and concerns about heavy debt, borrowing costs and access to financing for its AI infrastructure expansion. Traders are divided between expecting further downside and betting on a rebound or short squeeze; some bulls point to reported GPU price increases as evidence of demand and pricing power.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a potential U.S.-Iran dealand doubts that an agreement is imminentdominate discussion, with traders linking the headlines and oil swings to QQQs sharp reversals. Some bought the bounce, while others called it a bull trap and pointed to tech/AI weakness and upcoming earnings as reasons for caution.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plans to pursue a public listing for financial-services arm Monee and launch an AI enterprise platform are drawing attention, but traders are divided over whether the separation could unlock value or leave SE with less attractive businesses; some also question whether existing shareholders would receive Monee shares. The discussion is amplified by SEs sharp selloff and concerns about insider sales and managements lack of buybacks, though traders disagree on what is driving the decline.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly earnings beat and higher full-year guidance have been overshadowed by a sharp share-price decline, with traders focusing on rising costs, weaker cash flow, and an insurance-business loss. The community is split between seeing strong orders and services demand as evidence of durable momentum and questioning whether that demand will translate into better margins and cash generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Equity

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

 Futures are lower, erasing much of yesterday's gain with both Nasdaq and Rusell lagging SPX, following a continued rollercoaster in Korea where stocks tumbled after the BOK hired rates for the first time in 3 years...

Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?

ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.

AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.

AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […]
The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One...

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH Research PLC

Bearish Sentiment

<ul class="summary-bullets"><li>Wells Fargo said competition down the line could limit the long-term commercial potential of its therapy for treatment-resistant depression.</li><li>The firm initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.</li><li>Wells Fargo forecasts more than $7 billion in peak sales for Madrigal Pharmaceuticals’ Rezdiffra.</li></ul>Wells Fargo initiated coverage on five biotechnology companies, expressing optimism on several late-stage drug developers focused on depression therapies, including Helus Pharma (HELP), GH Research (GHRS), and Definium Therapeutics (DFTX), while taking a more cautious stance on Compass Pathways (CMPS).<h2 class="st-heading-2">Compass Could Face Competitive Challenges</h2>According to The Fly, Wells Fargo initiated Compass Pathways with an ‘Equal Weight’ rating and a $13 price target, implying a 12% upside potential from current levels.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up 2.6% at the time of writing.Analyst Benjamin Burnett said the company’s COMP360 therapy for treatment-resistant depression is likely to meet the U.S. Food and Drug Administration’s (FDA) approval standard after two positive Phase 3 studies. The latest trial, reported in February 2026, showed that two 25 mg doses of COMP360 delivered a statistically significant and clinically meaningful reduction in depression symptom severity, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with the 1 mg dose.However, he noted that the treatment’s efficacy appears comparable to Johnson &amp; Johnson’s Spravato, while competition from follow-on therapies could limit its long-term commercial opportunity.Retail sentiment for CMPS on Stocktwits turned ‘bearish’ from ‘neutral’ a day earlier. The stock has seen strong buying interest so far this year, gaining more than 76%.<h2 class="st-heading-2">HELP Stock Has Attractive Risk/Reward Profile Ahead Of Phase 3 Results</h2>Wells Fargo initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.The firm thinks COMP360 data provide validation for Helus’ HLP003 in treatment-resistant depression.&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> was up around 5% at the time of writing.Last week, Helus Pharma completed enrollment in its Phase 3 Approach Trial evaluating HLP003 in adults with moderate to severe major depressive disorder who have not responded adequately to antidepressants. The company expects to report Phase 3 results in the fourth quarter.The firm sees an attractive risk-reward profile for the shares ahead of the topline results.Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes. The stock has shed roughly 3% so far this year.<h2 class="st-heading-2">Wells Fargo Is Bullish On GH Research Despite Investor Skepticism</h2>The firm started GH Research with an ‘Overweight’ rating and a $44 price target, implying a 56% upside potential from its current levels.&nbsp;<a href="https://stocktwits.com/symbol/GHRS">GHRS stock</a> is up around 3.2%.In June, the company reported results of a Phase 2a trial for postpartum depression. The treatment met its primary endpoint, reducing depression scores by an average of 35.4 points by Day 8. The treatment was well tolerated, with no serious adverse events or treatment-related suicidal thoughts or behavior.Despite an over 12% increase in the stock price since then, Wells Fargo said the current valuation suggests investors remain unconvinced that the company’s encouraging Phase 2b depression data will be replicated in Phase 3 trials.The stock has gained more than 112% so far this year, while its retail sentiment on Stocktwits turned ‘neutral’ from ‘bullish’ a day earlier.<h2 class="st-heading-2">Definium Therapeutics Is Riding The Psychiatry Trend</h2>Wells Fargo also started coverage of Definium Therapeutics with an ‘Overweight’ rating and a $68 price target, indicating a 51% upside potential. The stock is currently up around 4%.The firm believes Spravato has validated the interventional psychiatry model for treating depression, creating room for new therapies.Definium’s lead candidate, DT120, met the primary endpoint in its Phase 3 Emerge trial in adults with major depressive disorder. Patients treated with DT120 saw a 13.3-point reduction in depression scores at six weeks, compared with a 5.2-point reduction in the placebo group. Wells Fargo believes the company is well positioned to benefit from growing demand for innovative mental health treatments.<a href="https://stocktwits.com/symbol/DFTX">DFTX shares</a> have gained more than 240% so far this year, while retail sentiment on Stocktwits has remained in the ‘bearish’ territory over the past 24 hours.<h2 class="st-heading-2">Madrigal’s Rezdiffra Has A Multi-billion-Dollar Sales Potential</h2>The firm launched coverage of Madrigal Pharmaceuticals with an ‘Overweight’ rating and a $685 price target, representing a 22% upside potential, while its stock is currently up around 3%.Wells Fargo forecasts more than $7 billion in peak sales for Rezdiffra, its lead medication to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.The firm also added that physician surveys indicate concerns about GLP-1 drugs and competitive pressures are overstated, supporting durable growth in what it expects to be a ‘multi-drug market.’Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/MDGL">MDGL</a> turned ‘bullish’ from ‘neutral’ a day earlier. The stock is down around 6% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-is-crashing-today-fda-briefing-casts-doubt-on-duchenne-cell-therapy-before-key-vote/cZZx1IOR76P">&nbsp;CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

While Johnson & Johnson’s stock (JNJ) has risen 25.6% so far in 2025, Roche’s U.S.-listed stock (RHHBY) has gained 20% over the same period. (Photo credit: Getty Images)

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Definium Therapeutics Inc.

Helus Pharma Inc.

Madrigal Pharmaceuticals Inc

Tema Neuroscience & Mental Health ETF

AdvisorShares Psychedelics ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$19.20
Prev Close	$18.28
Open	$18.30
Dividend Yield	0.00%
50-Day Moving Average	$25.81
Beta	0.97
Avg. Volume	278,062.06
PE Ratio	-18.52

52-Week High	$31.44
52-Week Low	$12.04
Market Capitalization	$1.25B
EPS (Annual)	-$0.7906
Price to Book	3.49
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GHRS Fundamentals